MyronSCzuczmanMD
Internal Medicine • Buffalo, NYHematology/Oncology
Professor of Medicine, SUNY Buffalo
Are you Dr. Czuczman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-3894
Summary
- Dr. Myron Czuczman, MD is an internist in Buffalo, New York. He is a Professor of Medicine at SUNY Buffalo.
Publications & Presentations
PubMed
- Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.Theingi M Thway, Jagadeesh Aluri, Bojan Lalovic, Chean E Ooi, Nicholas Sauter
Clinical and Translational Science. 2025-03-01 - 5 citationsDurvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz
Cancer Reports. 2023-01-01 - 9 citationsBiomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.Aliyah R. Sohani, Matthew J. Maurer, Sharmila Giri, Brandelyn Pitcher, Amy Chadburn
The American Journal of Surgical Pathology. 2021-03-01
Press Mentions
Citius Enters Partnership for Phase I/Ib Solid Tumour Treatment TrialSeptember 23rd, 2022- Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777)October 13th, 2021
- Citius Pharmaceuticals : Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-cell Lymphoma and Other Cancer Indications (Form 8-K)September 7th, 2021
- Join now to see all
